Corporate Member Update: Merck

Approval of KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph)

KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph) Subcutaneous Injection 165 mg/2,000 units per mL is indicated for use in adult patients across most solid tumor indications for KEYTRUDA® (pembrolizumab) Injection 100 mg—whether alone or in combination with other therapies.

• One such indication is the adjuvant treatment of adult patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

To read the full memo, please click here.